Our Technology
Contraria Biotech exploits integrated technological platforms to identify, select and develop future approaches to deliver effective products.
modified Outer Membrane Vesicles (mOMV)
A versatile technology platform that exploits bacteria for the production of self adjuvanting vesicles able to deliver antigenic molecules.
This technology has great advantages for product development, including large-scale, cost-effective production. mOMV have demonstrated good tolerability and high immunogenicity in humans.
Solutions to fight AMR pathogens
Bacterial infections remain a serious threat for humanity. The increasing impact of antimicrobial resistance could create a global crisis with 10 million death per year in 2050.
We will use our R&D platforms to develop vaccines and immuno-therapeutics against Gram-negative bacteria that have a high level of antimicrobial resistance worldwide.
Biotech Lab 4.0
Vaccine development by design
A revolutionary way to accelerate, control and implement processes in real time by creating intelligent networks of equipment and open data systems that govern each other.
Contraria Biotech Lab 4.0 is a new model of early stage development for new biopharmaceutical products, particularly those containing, or consisting of, recombinant proteins (e.g. vaccines, immuno-therapeutics, ), and a new model of pre-clinical R&D.
They Talk About Us
Latest News
-
AchilleS Vaccines cambia nome e diventa Contraria Biotech
Siena – 05/06/2024. AchilleS Vaccines, azienda biotech impegnata nello sviluppo sostenibile di vaccini e biofarmaci sicuri contro le malattie infettive, annuncia il suo rebranding e
-
Presentato al CdA della Fondazione Biotecnopolo di Siena il Progetto Prometheus. Filiera biotecnologica strategica nazionale permanente
Siena – 20/03/2024. Ieri, 19 marzo 2024, è stato inviato ufficialmente al Consiglio di Amministrazione della Fondazione Biotecnopolo di Siena il progetto Prometheus. Il progetto
-
Penta Teams Up with IAVI and Achilles Vaccines to Develop New Treatments for HIV, Emerging Infections and Neglected Diseases
Padova, Italy, 01/02/2024 – Penta - Child Health Research announced a new collaboration with IAVI and Achilles Vaccines to accelerate the development of treatments for